FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPRO	JVAL				
OMB Number:	3235-0287				
Estimated average burd	en				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

1. Name and Address of Reporting Person* <u>Dake Benjamin T</u>					2. Issuer Name and Ticker or Trading Symbol Aerovate Therapeutics, Inc. [ AVTE ]									all appli Directo	,		10% O	wner			
(Last) C/O AEI	,	rst) (	(Middle	<i>'</i>		Date of /18/20		est Tra	nsaction	saction (Month/Day/Year)					below)			Other (specify below)			
930 WINTER STREET, SUITE M-500					4 1	If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
(Street) WALTHAM MA 02451				- II Americinent, Date of Original Flied (Montuiday/Teal)								Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting  Person					on				
(City)	(S	tate) (	(Zip)																		
		Tab	le I - I	Non-Deri	vative	e Sec	uriti	ies A	cquire	d, D	isposed o	of, or B	enefic	ially	Owned	t					
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y				Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Benefic		ies :ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(Instr. 4)				
Common Stock 10/18/202			022	2 M <sup>(1)</sup> 5,705 A		\$2.	14	5,705		D											
Common Stock 10/18/202			022				S <sup>(1)</sup>		5,705	D	\$21.08	0 0				D					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		De Se (In	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Owner Form: Direct or Indi (I) (Inst	Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amou or Numb of Share	er							
Stock Option (Right to	\$2.14	10/18/2022			M <sup>(1)</sup>			5,705	(3)	)	04/01/2031	Commo	n 5,70	5	\$0	299,16	6	D			

## **Explanation of Responses:**

- 1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
- 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$20.665 to \$21.355, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 3. A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly

## Remarks:

Officer Title: President, Chief Operating Officer and Secretary

/s/ George A Eldridge,

10/20/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.